2. Search Result
Search Result
Results for "

SRF

" in MedChemExpress (MCE) Product Catalog:

10

Inhibitors & Agonists

2

Inhibitory Antibodies

1

Recombinant Proteins

1

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99533
    Urabrelimab

    SRF-231; SRF231

    		 Interleukin Related Cancer
    Urabrelimab (SRF231) is a fully human anti-CD47 monoclonal antibody that blocks the CD47-SIRP interaction .
    Urabrelimab
  • HY-153078
    MRTF/SRF-IN-1

    		Ras Cancer
    MRTF/SRF-IN-1 (example 41) is an inhibitor of both myocardin-related transcription factor and serum response factor (MRTF/SRF). MRTF/SRF-IN-1 can be used for research for preventing cancer and fibrosis .
    MRTF/<em>SRF</em>-IN-1
  • HY-118748
    Suprafenacine

    SRF

    		 Microtubule/Tubulin Cancer
    Suprafenacine is a cell permeable, tubulin-destabilizing molecule which bind microtubules at the colchicine-binding site and inhibit polymerization. Suprafenacine can induce G2/M cell cycle arrest and apoptosis, and can be used for cancer research .
    Suprafenacine
  • HY-P990024
    Casdozokitug

    SRF-388

    		 Interleukin Related Cancer
    Casdozokitug (SRF-388) is an IgG1κ antibody targeting IL27 .
    Casdozokitug
  • HY-RS13760
    SRF Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    SRF Human Pre-designed siRNA Set A contains three designed siRNAs for SRF gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    SRF Human Pre-designed siRNA Set A
    SRF Human Pre-designed siRNA Set A
  • HY-120855
    CCG-100602
    1 Publications Verification

    		 Ras Cardiovascular Disease
    CCG-100602 is a specific inhibitor of myocardin-related transcription factor A/serum response factor (MRTF-A/SRF) signaling. CCG-100602 specifically block MRTF-A nuclear localization and thus inhibit the fibrogenic transcription factor SRF .
    CCG-100602
  • HY-108361
    CCG-203971

    		Ras Inflammation/Immunology Cancer
    CCG-203971 is a second-generation Rho/MRTF/SRF pathway inhibitor. CCG-203971 potently targets RhoA/C-activated SRE-luciferase (IC50 =6.4 μM). CCG-203971 inhibits PC-3 cell migration with an IC50 of 4.2 μM. Potential anti-metastasis Agent .
    CCG-203971
  • HY-130011
    CCG-232964

    		ROCK Ras Neurological Disease Cancer
    CCG-232964 is an orally active inhibitor of Rho/MRTF/SRF. CCG-232964 inhibits LPA-induced CTGF gene expression .
    CCG-232964
  • HY-13991
    CCG-1423
    5+ Cited Publications

    		 Ras Apoptosis Cancer
    CCG-1423 is an inhibitor of Rho/MRTF/SRF pathway. CCG-1423 shows activities in several cancer cells. CCG-1423 is a promising lead compound for the development of novel pharmacologic tools, and it can be used for the research of cancer and diabetes .
    CCG-1423
  • HY-111432
    CCG-232601

    		Ras Others
    CCG-232601 (compound 8f) is a potent and orally active Rho/MRTF/SRF transcriptional pathway inhibitor. CCG-232601 inhibits the development of Bleomycin-induced dermal fibrosis in mice. CCG-232601 has the potential for the research of antifibrotic for systemic scleroderma .
    CCG-232601

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: